Kidswell Bio Corporation (TYO:4584)

Japan flag Japan · Delayed Price · Currency is JPY
274.00
+9.00 (3.40%)
At close: Mar 6, 2026
Market Cap13.59B +206.7%
Revenue (ttm)7.06B +276.4%
Net Income23.97M
EPS0.51
Shares Out49.61M
PE Ratio567.06
Forward PE16.07
Dividendn/a
Ex-Dividend Daten/a
Volume717,600
Average Volume1,532,320
Open260.00
Previous Close265.00
Day's Range259.00 - 274.00
52-Week Range93.00 - 417.00
Beta1.25
RSI56.74
Earnings DateFeb 12, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 37
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4584
Full Company Profile

Financial Performance

In fiscal year 2025, Kidswell Bio's revenue was 5.08 billion, an increase of 223.90% compared to the previous year's 1.57 billion. Losses were -21.00 million, -96.07% less than in 2022.

Financial Statements